All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Targeting OXPHOS With Lixumistat Could Lessen Chemoresistance in Pancreatic Cancer

November 20th 2025

Shubham Pant, MD, MBBS, and Ryan W. Huey, MD, MS, discuss OXPHOS pathway inhibition in pancreatic cancer with lixumistat.

FDA Grants Accelerated Approval to Sevabertinib in HER2-Mutated Nonsquamous NSCLC

November 19th 2025

The FDA approved sevabertinib for previously treated, nonsquamous non–small cell lung cancer with HER2 TKD activating mutations.

FDA Grants Full Approval to Tarlatamab for Extensive-Stage Small Cell Lung Cancer

November 19th 2025

The FDA has granted traditional approval to tarlatamab-dlle (Imdelltra) for the treatment of select patients with ES-SCLC.

Modified Daratumumab-Based Quadruplet Shows Feasibility in Older Multiple Myeloma

November 19th 2025

Andrew Yee, MD, discusses data for a modified four-drug regimen studied in older patients with newly diagnosed multiple myeloma.

FDA Approves Daratumumab and Hyaluronidase-fihj in Newly Diagnosed Light Chain Amyloidosis

November 19th 2025

The FDA has granted traditional approval to daratumumab and hyaluronidase-fihj with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain amyloidosis.

European Commission Approves Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

November 19th 2025

The European Commission has approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma.

Adjuvant Cemiplimab Cleared in EU for CSCC With High Recurrence Risk After Surgery and Radiation

November 19th 2025

Cemiplimab wins EU approval after C-POST shows DFS gains for high-risk CSCC, marking the first effective adjuvant immunotherapy option.

FDA Approves Selumetinib for Adult NF1-Associated Plexiform Neurofibromas

November 19th 2025

The FDA approved selumetinib for the treatment of adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Shaping the Future of Care for Neuroendocrine Tumors

November 19th 2025

Fox Chase Cancer Center’s Namrata ‘Neena’ Vijayvergia, MD, an expert in gastrointestinal cancers and rare NETs, was recently recognized by two NET advocacy groups for her contributions to the field.

Beyond the Biopsy: A New Blood Test Is Redefining the Fight Against Relapsed AML

November 19th 2025

Liquid biopsy offers a revolutionary approach for detecting relapse in AML patients post-stem cell transplant, potentially enhancing early intervention.

Genomic, Immune, Epigenetic Features Drive Treatment Decision-Making in High-Risk NSCLC Subtypes

November 19th 2025

Benjamin Herzberg, MD discusses challenges and evolving strategies for managing high-risk NSCLC subsets, underscoring the value of genomic testing.

New Angio-CT Technology Integrates Cutting-Edge Imaging to Enhance Patient Care

November 18th 2025

The new angiography-CT suite at Huntsman Cancer Institute is a regional first, expanding advanced interventional radiology capabilities in the Mountain West.

Giredestrant Becomes First Oral SERD to Show iDFS Benefit As Adjuvant Therapy in Early ER+, HER2-Negative Breast Cancer

November 18th 2025

The phase 3 lidERA trial shows improved iDFS with giredestrant vs standard therapy in early ER-positive, HER2-negative breast cancer.

FDA Grants Fast Track Designation to DPTX3186 for Gastric Cancer

November 18th 2025

DPTX3186, a first-in-class oral condensate modulator, has received FDA fast track designation in gastric cancer.

FDA Approves Epcoritamab for R/R Follicular Lymphoma

November 18th 2025

The FDA approved epcoritamab plus rituximab and lenalidomide for relapsed or refractory follicular lymphoma indications.

Newer Generations, Resistance Profiling, and Toxicity Trade-offs Guide Modern TKI Selection/Use in Oncogene-Driven NSCLC

November 18th 2025

Alexander Drilon, MD, summarized approaches to TKI selection in NSCLC displaying oncogenic driver alterations for both TKI-pretreated and -naive patient populations.

FDA Awards Orphan Drug Designation to ZEN-3694 for NUT Carcinoma

November 18th 2025

ZEN-3694 obtained orphan drug designation from the FDA for the treatment of NUT carcinoma.

Gedatolisib NDA for HR+ PIK3CA Wild-Type Advanced Breast Cancer Has Been Submitted to the FDA

November 18th 2025

Gedatolisib’s NDA filing to the FDA is supported by VIKTORIA-1 data showing marked PFS improvements in HR+/HER2– advanced breast cancer.

FDA Approval of Lurbinectedin/Atezolizumab as First-Line Maintenance Expands Limited Postinduction Arsenal for ES-SCLC

November 18th 2025

Joshua K. Sabari, MD, discusses the FDA approval of lurbinectedin plus atezolizumab as first-line maintenance therapy in extensive-stage SCLC.

Tafasitamab Approaches EU Approval for Relapsed/Refractory Follicular Lymphoma

November 17th 2025

Tafasitamab plus lenalidomide/rituximab cut progression risk by over 50% in relapsed follicular lymphoma, supporting its approval as a key second-line option.